CA-CYARA
5.4.2022 15:02:09 CEST | Business Wire | Press release
Cyara , provider of the award-winning Automated Customer Experience (CX) Assurance Platform, today closed its acquisition of industry-leading automated chatbot testing company, Botium , which adds chatbot and conversational AI testing capabilities to its portfolio, further solidifying its position as the global leader in the CX testing and assurance market.
The chatbot market is rapidly growing, with a 22.5% compound annual growth rate (CAGR) projected between 2020 and 2027. The increased use of chatbots and natural language understanding (NLU) throughout the digital customer journey has created the need for solutions that can efficiently and effectively test and monitor the performance of chatbots and conversational AI. Botium provides solutions that solve this unique need to Cyara, bolstering the comprehensiveness of its automated CX assurance capabilities across digital channels and making it an ideal addition to Cyara’s existing portfolio of solutions that enable customers to assure their CX is flawless.
The acquisition is part of Cyara’s strategic plan for international growth and product innovation, fueled by its recent $350 million growth investment . Cyara’s mission is to deliver a complete CX assurance platform that will test customer journeys cohesively, regardless of channel or whether those journeys are delivered through a single platform or multiple best-of-breed solutions. More than 100 million chatbot tests have been executed on Botium Box and the company has a 92% recurring customer rate. Botium brings over 1,500 Botium Box customers, in addition to 185,000 open source users. Additionally, the acquisition expands Cyara’s existing international presence to Central Europe, with Botium’s offices in Austria.
“This acquisition is a major milestone in Cyara’s growth and it further enhances our ability to help companies assure their end-to-end customer experiences,” said Alok Kulkarni, CEO of Cyara. “We are so pleased to join forces with Botium to provide an easy way for enterprises to ensure their CX through an IVR, chatbot, agent-based phone, or some combination of voice and digital channels is flawless.
Botium, named in 2021 as a Gartner Cool Vendor in Conversational and Natural Language Technologies , brings deep expertise in chatbots, conversational AI and NLU to Cyara. Its skilled workforce will join Cyara’s digital CX assurance development team. Chatbots and conversational AI present unique challenges for testing and monitoring. Given all the possible permutations that could occur, manual testing is simply not possible. Botium’s automated chatbot testing improves the quality of the chatbot, ensuring it performs as expected, all while reducing the efforts of enterprise IT teams and shortening the time-to-market for chatbots. Its solution provides added value in every phase of the customers’ bot development lifecycle.
“We see Cyara as a natural fit since it is a forward-looking company that’s well-positioned to lead the digital CX assurance category,” said Christoph Börner, Co-founder and CEO of Botium. “The Botium team is made up of talented developers and engineers, and joining Cyara’s team will give us additional resources to expand our efforts in developing innovative solutions for testing chatbots and conversational AI, as well as reaching a wider global customer base.”
To learn more about Cyara’s CX assurance capabilities and the acquisition news, please visit: https://cyara.com/botium-box/ .
About Cyara’s Automated CX Assurance Platform
The Cyara Automated CX Assurance Platform is used by some of the world’s top brands to automate and accelerate testing of the CX they deliver, measure and optimize the quality of digital and voice channels, and then assure flawless omnichannel customer journeys from beginning to end. CX experts use Cyara’s cloud-based platform to define customer journeys that Cyara’s automated bots engage with by testing the network, applications, and even back-end data systems that power those journeys. Any issues that a customer may experience in how those journeys perform are identified so organizations can resolve them before they impact a customer.
About Cyara
As the world’s leading Automated CX Assurance platform provider, Cyara accelerates the delivery of flawless customer journeys across digital and voice channels while reducing the risk of customer-facing defects. Every day, the most recognizable brands in the world trust the Cyara Platform to deliver customer smiles at scale. For more information, please visit cyara.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005087/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom